<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129307">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01728376</url>
  </required_header>
  <id_info>
    <org_study_id>DAP-PEDBAC-11-02</org_study_id>
    <nct_id>NCT01728376</nct_id>
  </id_info>
  <brief_title>A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus</brief_title>
  <official_title>A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intent of this study is to describe the safety and efficacy of daptomycin versus
      standard of care (SOC) in pediatric subjects aged 2-17 years with bacteremia caused by S.
      aureus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Staphylococcus aureus causes a series of invasive diseases in adults and children, including
      bacteremia.   Infections due to S. aureus in children, particularly those due to methicillin
      resistant S. aureus (MRSA), are a growing world-wide public health concern.

      Daptomycin, a cyclic lipopeptide antibacterial agent, shows rapid in vitro bactericidal
      activity with concentration-dependent killing for Gram-positive organisms, including S.
      aureus. Surveillance studies have demonstrated a daptomycin MIC90 of 0.5µg/ml for both
      methicillin-susceptible Staphylococcus aureus (MSSA) and MRSA with &gt;99% of MRSA isolates
      being categorized as susceptible by the Food and Drug Administration (FDA), European
      Committee of antimicrobial susceptibility testing (EUCAST) and Clinical and Laboratory
      Standards Institute (CLSI) breakpoints (5). Clinical trials in adults demonstrated that
      daptomycin was safe and efficacious in complicated skin and skin structure infections
      (cSSSI) and bloodstream infections caused by S. aureus, including right-sided infective
      endocarditis (RIE). However, information on the safety and efficacy of daptomycin for use in
      children is lacking.

      The intent of this study in children is to confirm the safety of daptomycin at mean steady
      state systemic exposures (AUC) similar to those reported for adults treated at 6 mg/kg for
      bacteremia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety of daptomycin measured by the incidence of treatment-emergent adverse events, vital signs, echocardiogram (if performed) and clinical laboratory tests, use of concomitant medications,physical and neurological exam results.</measure>
    <time_frame>Administration of first dose through the last follow-up visit; an expected average of 9-11 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of daptomycin will be based on Investigator's assessment of clinical response (cure, improved, failure or non-evaluable) at the Test of Cure (TOC) visit.</measure>
    <time_frame>EOT(after completion of i.v. or oral therapy, up to 6 weeks) and TOC (7-14 days after the last dose of study medication)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Daptomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care; comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vancomycin, Semi-synthetic penicillin,First-generation cephalosporins, Clindamycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>i.v daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 2-6 years)</description>
    <arm_group_label>Daptomycin</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator (Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin)</intervention_name>
    <description>Administered per standard of care</description>
    <arm_group_label>standard of care; comparator</arm_group_label>
    <other_name>Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be included in this study, participants must:

          -  Sign a parental consent form; if appropriate, sign an assent form

          -  Be between 2 and 17 years of age

          -  Have proven or probable bacteremia caused by Staphylococcus aureus based on the
             traditional culture result, rapid diagnostic test or Gram stain

          -  If female of childbearing potential, must not be pregnant or nursing and take
             appropriate measures to not get pregnant during the study

          -  If male, must take appropriate measures to not get partner pregnant

          -  Able to comply with the protocol requirements

        Exclusion Criteria:

        Participants will not be allowed into the study if they:

          -  Have received a certain amount of antibacterial therapy specific for current
             bacteremia unless it is demonstrated that the organism is resistant to the given
             antibacterial;

          -  Anticipate to require other antibiotics that may be potentially effective against S.
             aureus;

          -  Have shock or hypotension unresponsive to standard therapy;

          -  Have received an investigational product or have participated in an experimental
             procedure within 30 days;

          -  Have an intolerance or hypersensitivity to daptomycin;

          -  Have renal insufficiency;

          -  Have prior history or current evidence of muscle damage (rhabdomyolysis; significant
             creatine phosphokinase (CPK) elevation);

          -  Have history of clinically significant muscular disease, nervous system or seizure
             disorder, including unexplained muscular weakness, history of peripheral neuropathy,
             Guillain-Barré or spinal cord injury;

          -  Have S. aureus pneumonia, empyema, meningitis, or endocarditis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Bokesch, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cubist Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Abbes</last_name>
    <phone>781-860-8201</phone>
    <email>claudia.abbes@cubist.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Children's Center at Maricopa Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amin Ostovar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Arrieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours/Al duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abigail Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diana Florescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kari Simonsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tsoline Kojaoghlanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron Children's Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James Nard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aurelia Balan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marian Michaels, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LeBonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandra Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lynne Eger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Sciences Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gloria Heresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Lopez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <zip>3000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gustavo Cesar Ezcurra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Clayton, Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jim Butttery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Graham Reynolds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville, Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mike Starr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte/Minas Gerias</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>São José do Rio Preto - sp</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Concepcion</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Puente Alto</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Sandoval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pablo Cruces, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nikos Spyridis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Roilides</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1086</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gariella Kiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edit Szikszay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aranka Bolyos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adi Klein-Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eli Somekh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dan Engelhard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Susanna Esposito</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrizia D'Argenio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pier-Angelo Tovo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bharu/ Kelantan</city>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Azlan Bin Husin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuching / Sarawak</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hock Hin Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tirza Areli De Leon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dora Estripeaut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Panama</city>
        <zip>0843-0167</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kathia Luciani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <zip>500063</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oana Falup-Pecurariu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horatiu Gocan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eugen-Sorin Boia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Ramos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Castello</city>
        <zip>12070</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Perez Iranzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Esplugues</city>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antoni Noguera-Julian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pablo Rojo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Gueishan Township</city>
        <state>Taoyuan County</state>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chen-Hsun Chiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Li-Min Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veerachai Watanaveeradej</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wanatpreeya Phongsamart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pope Kosalaraksa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Pathum thanee</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Auchara Tangsathapornpong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valery Digtyar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ganna Senatorova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Natalia Karpenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Borys Bezkaravaynyy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dmytro Dmytriiev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Panama</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>November 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin-2-phosphate</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
